Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
about
Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationEmerging targeted therapies for glioma.A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patientsGeometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma PatientsImplications of neurovascular uncoupling in functional magnetic resonance imaging (fMRI) of brain tumors.Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis.Current status and future directions of anti-angiogenic therapy for gliomasGlioblastoma: Defining Tumor Niches.Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.Relationship Between Cytogenetic Complexity and Peritumoral Edema in High-Grade AstrocytomaSerial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.govLumbar puncture-administered resveratrol inhibits STAT3 activation, enhancing autophagy and apoptosis in orthotopic rat glioblastomas.Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cellsMetabolic origins of spatial organization in the tumor microenvironment.Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy.Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance.Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.Cyclooxygenase-2 in glioblastoma multiforme.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.GPR133 (ADGRD1), an adhesion G-protein-coupled receptor, is necessary for glioblastoma growth.Angiogenesis inhibitors in tackling recurrent glioblastoma.Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials.Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.Pleiotrophin is a driver of vascular abnormalization in glioblastoma.Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.Contemporary management of high-grade gliomas.A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma.Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy.Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment.Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.
P2860
Q26781833-727103FA-85DE-493A-B0A4-3110C77E5EA9Q30241853-4C88BB72-0CA8-4F75-AC5D-0CD31840A626Q30300114-D5A8ADB9-D128-4285-94E9-6DC6FEDB5CB8Q33576750-2A984423-04A4-4346-892F-BA91B9F25DC6Q36111620-AE52DE99-323F-4F43-8310-028CE426CFAFQ36368541-8F0C5C1E-7B9D-4AB6-ACEA-0109426C738DQ36585924-CCA89887-E516-4BDD-923F-4740BD0BF0A3Q36618235-18C82A5A-6B16-44EA-AC50-88C88902C6D4Q36796616-F7640131-5E82-4DB6-94B2-64B8C90AB865Q36831553-BE2E335F-A6ED-4639-942A-BEB79707D185Q36831642-0917484A-F4A0-4AC1-B504-CDEFE31F21D2Q37231526-208DEAEA-1DE5-4DF8-8BB7-88AF3F12CB19Q37348479-1CD4E1BB-A4A9-47F8-B313-A7F9EC84EB8AQ37555973-83C7372C-FC58-4837-9ACD-99FE2D345FD8Q37689021-EEFC8CB4-FD5E-4173-862A-2AEEAF74D44DQ37695245-052E7F5A-0AC9-406E-A6E0-7333225B771FQ37711597-03819DAB-D78F-41AA-AA37-AB400859891FQ38599484-09A1FEC7-5B41-40F3-9F7F-E0242F9A86F5Q38718044-9A1F6FDE-857B-41AF-B95A-CA97608DC7D8Q38720819-089FD400-E9B2-4A94-B567-E5CCE27FC832Q38794595-6B766100-8724-470B-A4D2-E88733611259Q38969912-6D0B0032-1F2C-401C-9F99-B03A4AF7C8B9Q39022941-76015875-71DA-4597-A8E5-0EFCCC71414DQ39225820-CCC8A1D9-0BDA-43B8-955E-2D5B6CB3C24BQ39254893-9940994D-9612-4ABD-94E7-B2283EA8B70BQ39259089-8A193F7E-B243-4C2E-83CF-9D76F314A206Q39339970-DADDF63B-F2AF-4C82-9433-943D44EDC531Q40497804-7F92AA84-0A7E-494A-8378-D42F8BD5BBAFQ41849797-C845819E-8C65-4F14-9EE5-EDD642EE3150Q42282790-91738B97-DC6F-4F6A-BEC1-B26D95D8DD05Q47781482-AA122115-402F-4008-83C7-E53CD767E94BQ47861428-C53C8A41-66DD-4768-B034-14BB4879380DQ47996105-A04E1E66-A5F6-40F8-9368-972EBC16D176Q48112689-CA24E821-8256-4393-BF88-0D99B98CFFF9Q48369496-D7311963-D5B6-42B1-A95D-1B3A8D62C07DQ48865058-BE833804-A3D2-4F4D-BEA3-F191EEB9E487Q50110970-01F6E3AB-BD11-4E55-A807-04B35D44E6C1Q51068702-6B4B6C35-A49E-432D-8593-321BF58C21BBQ52590668-5C6CCABE-775F-432E-A7F9-8D4E29C2E830Q52615294-38603222-E673-4E72-8220-64559A5C20EA
P2860
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Lessons from anti-vascular end ...... in patients with glioblastoma.
@ast
Lessons from anti-vascular end ...... in patients with glioblastoma.
@en
type
label
Lessons from anti-vascular end ...... in patients with glioblastoma.
@ast
Lessons from anti-vascular end ...... in patients with glioblastoma.
@en
prefLabel
Lessons from anti-vascular end ...... in patients with glioblastoma.
@ast
Lessons from anti-vascular end ...... in patients with glioblastoma.
@en
P2093
P2860
P356
P1476
Lessons from anti-vascular end ...... in patients with glioblastoma
@en
P2093
Christine Lu-Emerson
Dan G Duda
Elizabeth R Gerstner
Jay S Loeffler
Jennie W Taylor
Rakesh K Jain
Tracy T Batchelor
P2860
P304
P356
10.1200/JCO.2014.55.9575
P407
P577
2015-02-23T00:00:00Z